Investigational drug · Phase 3
ASTX030
Also called: cedazuridine + azacitidine
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "ASTX030"
First trial start
2020
May 21, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ASTX030", any sponsor or status.
Conditions studied
As listed on its trial records.
- Myelodysplastic Syndromes
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome/Neoplasm
- Chronic Myelomonocytic Leukemia
Approved drugs for the same conditions: Acute myeloid leukemia · Myelodysplastic syndromes · Oncology · Hematology and blood cancers · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "ASTX030" as an intervention, largest first.
- A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)Pivotal-lookingRecruiting
Taiho Oncology, Inc.Industry
NCT04256317 · 316 participants (planned) · Start May 21, 2020 · Primary completion Nov 1, 2027
Drug: Azacitidine; ASTX030 (cedazuridine + azacitidine) and 4 more · For: Myelodysplastic Syndromes; Acute Myeloid Leukemia; Myelodysplastic Syndrome/Neoplasm and 1 more
Sites: Los Angeles, California; Orange, California; New Haven, Connecticut · 73 sites in all
Taiho Pharmaceutical Co., Ltd.Industry
NCT04608110 · 59 participants (planned) · Start Oct 30, 2020 · Primary completion Dec 2027
Drug: ASTX030 (AZA + CED); ASTX030 (AZA + CED) and 1 more · For: Myelodysplastic Syndrome (MDS)
Sites: Bunkyō City, Japan; Fukushima, Japan; Iruma, Japan · 10 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review.
Haumschild R, Kennerly-Shah J, Barbarotta L, et al. · J Oncol Pharm Pract 2024
Also in development for Myelodysplastic Syndromes
- AND017Phase 36 trials
Kind Pharmaceuticals LLC · Anemia Due to Chronic Kidney Disease, β -Thalassemia, Cancer-Related Anemia
- ElriterceptTAK-226, KER-050Phase 36 trials
Takeda · Myelodysplastic Syndromes, Myelofibrosis, Anemia
- BL-M11D1Phase 32 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Acute Myeloid Leukemia, Myelodysplastic Syndromes
- RoxadustatFG-4592, ASP1517Phase 32 trials
Astellas · Chronic Kidney Disease, Renal Anemia, Myelodysplastic Syndromes
- RimiducidAP1903Phase 23 trials
Bellicum Pharmaceuticals · Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Leukemia, Acute Myeloid (AML), Child
- bexmarilimabFP-1305Phase 22 trials
Faron Pharmaceuticals Ltd · Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- DISC-0974Phase 22 trials
Disc Medicine, Inc · Anemia, Inflammatory Bowel Disease (IBD), Inflammatory Bowel Disease (IBD); Anemia
- OfirnoflastHT-6184Phase 22 trials
Halia Therapeutics, Inc. · Myelodysplastic Syndromes, Anemia, Myelodysplastic Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.